Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/42B98B0C096DA2AE57A4B3AAAD135DF9FE9A77B97B58062D376BEB3613B4B3F1E2F09013E9E015485B4DEC17F4436081http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/42B98B0C096DA2AE57A4B3AAAD135DF9FE9A77B97B58062D376BEB3613B4B3F1E2F09013E9E015485B4DEC17F4436081http://www.w3.org/2000/01/rdf-schema#comment"Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P < .0001) tumor grade (P=.001) T staging (P < .0001) N staging (P = .002) and a trend of better M staging (P = .053) than those in COL5A2 high expression group. These results indicated that COL5A2 might promote the progression of Bladder Cancer cells."xsd:string
http://purl.uniprot.org/uniprot/#_45C1484C81FA587AF0C55FAC3624FAC3C3E5966CBA9577B867637CDC1835D26E366F72A7B2F49594FF7B8999CDAAE0D0http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/42B98B0C096DA2AE57A4B3AAAD135DF9FE9A77B97B58062D376BEB3613B4B3F1E2F09013E9E015485B4DEC17F4436081
http://purl.uniprot.org/uniprot/Q5PR22http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/42B98B0C096DA2AE57A4B3AAAD135DF9FE9A77B97B58062D376BEB3613B4B3F1E2F09013E9E015485B4DEC17F4436081
http://purl.uniprot.org/uniprot/#_Q5PR22-mappedCitation-29517678http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/42B98B0C096DA2AE57A4B3AAAD135DF9FE9A77B97B58062D376BEB3613B4B3F1E2F09013E9E015485B4DEC17F4436081